Johnson & Johnson's (NYSE: JNJ) $20.3 billion in revenue in the third quarter was $300 million higher than anticipated, and its $2.05 in adjusted earnings per share in the period was $0.02 better than industry watchers' estimates. The company's top- and bottom-line performance is encouraging because its best-selling drug, Remicade, is facing fierce competition and its consumer goods and medical device businesses are only growing by single digits.